Nektar Therapeutics (NKTR) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Nektar Therapeutics in October 2026.
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar Therapeutics (NKTR) Stock Forecast
Analyst price target, next 12 months
$117.10
+214.6% vs today's $37.22
Price range over the last 12 months
Close to its 12-month low
Analysts covering Nektar Therapeutics have a consensus 12-month target of $117.10, above the current price of $37.22.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying NEKTAR THERAPEUTICS' stock due to significant potential for growth.
Financial Health
Nektar Therapeutics is generating strong revenue and cash flow, reflecting healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NKTR
RNA Stocks (M&A Targets) Could See Premium Valuations
Novartis's $12 billion acquisition of Avidity Biosciences underscores the high value of RNA-based treatments for rare diseases. This deal could spark a wave of similar acquisitions, creating opportunities for other biotech companies with innovative RNA platforms.
Published: 27 October 2025
Explore BasketWhy invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
